'CSI' technology holds potential in everyday medicineAugust 21, 2012
The report on technology already incorporated into instruments that miniaturize room-size lab instrumentation into devices the size of a shoebox was part of the 244th National Meeting & Exposition of the American Chemical Society, the world's largest scientific society. The meeting, which features about 8,600 reports with an anticipated attendance of 14,000 scientists and others continues here through Thursday.
"With both of the instruments we developed, no sample preparation is needed, which reduces analysis time from as much as several hours per sample to just a few seconds," said Graham Cooks, Ph.D., who led the research team. "Rapid results are critical when a surgeon is operating on a brain tumor or when chemotherapy patients are being treated with powerful drugs that must be administered at precise levels."
The instrument called a "desorption electrospray ionization" mass spectrometer, or DESI, was featured on both CSI and CSI: Miami as a tool to analyze fingerprints. However, this portable instrument can do so much more. It's about the size of a shoebox and does not change or destroy the sample that is analyzed. Cooks' students have even carried it into a grocery store and held it close to the outer surfaces of fruit and vegetables to detect pesticides and microorganisms. The team also used it to identify biomarkers for prostate cancer and to detect melamine, a potentially toxic substance that showed up in infant formulas in China in 2008 and in pet food in the U.S. in 2007. In addition, DESI can detect explosives on luggage.
Now, Cooks' team at Purdue University is teaming up with collaborators led by Nathalie Y. R. Agar, Ph.D., at Harvard University to test the instrument in the operating room during brain cancer surgery, comparing it with the gold standard - traditional analysis of tissue samples by pathologists.
"These procedures are among the longest of all surgical operations, and this new technology offers the promise of reducing the time patients are under anesthesia," Cooks explained. "DESI can analyze tissue samples and help determine the type of brain cancer, the stage and the concentration of tumor cells. It also can help surgeons identify the margins of the tumor to assure that they remove as much of the tumor as possible. These are early days, but the analysis looks promising."
The other instrument under development in Cooks' lab is a "PaperSpray ionization" mass spectrometer. The researchers are using this new device to monitor the levels of chemotherapy drugs in patients' blood in real time. "Many cancer drugs have relatively narrow therapeutic ranges, so they need to be in the blood at certain levels to work properly," he noted. "But at present, that information is not obtained in real time, so a patient could end up with too little or too much of the drug in his or her body."
For a video of PaperSpray, click here: http://www.youtube.com/watch?v=BHcMbFyHxTc
Both the DESI and PaperSpray mass spectrometers work in a similar way. To weigh chemicals, mass spectrometers need to ionize, or give a positive or negative charge to a substance. Mass spectrometers usually do this inside the instrument under a vacuum without air. But DESI and PaperSpray can do this so-called ionization process out in the open. This allows scientists much more flexibility. DESI and PaperSpray also can do analyses without separating out all of the chemicals in a sample first (unlike conventional instruments), which provides quick results. They are also very easy to operate. "You just point and shoot," said Cooks.
Currently, Cooks' team is testing to see whether DESI can provide different information compared to what pathologists can provide by looking at human tissues under a microscope. In addition, the researchers are testing PaperSpray on patients' blood samples, though Cooks points out that the device also could measure the levels of drugs of abuse or pharmaceuticals in urine or other body fluids.
American Chemical Society
Related Chemotherapy Current Events and Chemotherapy News Articles
Clinical waste may prove valuable for monitoring treatment response in ovarian cancer
A microchip-based device developed by Massachusetts General Hospital (MGH) investigators may greatly simplify the monitoring of patients' response to treatment for ovarian cancer - the most lethal form of gynecologic cancer - and certain other malignancies.
Economic factors may affect getting guideline-recommended breast cancer treatment
Women with interruptions in health insurance coverage or with low income levels had a significantly increased likelihood of failing to receive breast cancer care that is in concordance with recommended treatment guidelines.
Targeted treatment can significantly reduce relapse in children with AML leukemia
The addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival in pediatric patients with acute myeloid leukemia (AML).
Novel drug regimen can improve stem cell transplantation outcomes
dding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber Cancer Institute.
Breakthrough in treating leukemia, lymphoma with umbilical cord blood stem cells
Donated umbilical cord blood contains stem cells that can save the lives of patients with leukemia, lymphoma and other blood cancers.
Ovarian cancer discovery deepens knowledge of survival outcomes
Researchers in the Women's Cancer Program at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute have identified a series of 10 genes that may signify a trifecta of benefits for women diagnosed with ovarian cancer and ultimately reflect improved survival outcomes.
UAlberta researchers uncover why combination drug treatment ineffective in cancer clinical trials
Medical researchers at the University of Alberta have discovered that combination drug therapy didn't work well in clinical trials for cancer patients because one drug was making the other drug ineffective.
Study finds that carbon monoxide can help shrink tumors and amplify effectiveness of chemotherapy
In recent years, research has suggested that carbon monoxide, the highly toxic gas emitted from auto exhausts and faulty heating systems, can be used to treat certain inflammatory medical conditions.
Pediatric infectious disease chief authors new vaccination guideline for immunocompromised patients
A new guideline released Thursday by the Infectious Diseases Society of America (IDSA) notes that most people with compromised immune systems are especially vulnerable to illness and should receive the flu shot and other vaccinations.
Treatment target identified for a public health risk parasite
In the developing world, Cryptosporidium parvum has long been the scourge of freshwater.
More Chemotherapy Current Events and Chemotherapy News Articles